Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Connetics’ Velac Is “Not Approvable” For Acne

This article was originally published in The Pink Sheet Daily

Executive Summary

The only issue raised in FDA’s “not approvable” letter was a positive carcinogenicity signal found in a study involving genetically altered mice, the company says. The acne treatment combines clindamycin and tretinoin.

You may also be interested in...

Stiefel Labs Adds Connetics’ Topical Delivery Technology With Acquisition Of Dermatology Firm

Completion of the $640 million acquisition combines Stiefel’s dermatology portfolio with Connectics’ patented drug delivery technology.

Purdue Signs On To Market Labopharm's Once-Daily Tramadol

Labopharm will receive up to $170 mil. under the licensing deal, including $20 mil. up front and $40 mil. upon NDA approval.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts